Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic-citrullinated-peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis;Étude de cohorte prospective des effets de l'infliximab sur le facteur rhumatoïde, les anticorps antipeptides cycliques citrullinés et les anticorps antinucléaires chez les patients ayant une polyarthrite rhumatoïde ancienne

Revue du Rhumatisme (Edition Francaise)

Volumn 76, Issue 5, 2009, Pages 410-416

  Bruns, Alexandra ^a   Nicaise Roland, Pascale ^a   Hayem, Gilles ^a   Palazzo, Elisabeth ^a   Dieudé, Philippe ^a   Grootenboer Mignot, Sabine ^a   Chollet Martin, Sylvie ^a   Meyer, Olivier ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Anti CCP; Antinuclear antibodies; Infliximab; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

EID: 65049086455     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2008.09.021     Document Type: Article

References (36)

1. Cash J.M., and Klippel J.H. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 330 (1994) 1368-1375
2. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
3. Charles P., Elliott M.J., Davis D., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163 (1999) 1521-1528
4. Maini R.N., and Taylor P.C. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 51 (2000) 207-229
5. Pittoni V., Bombardieri M., Spinelli F.R., et al. Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 61 (2002) 723-725
6. Saint Clair E. Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis 61 (2002) 67-69
7. Chen H.A., Lin K.C., Chen C.H., et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 35-39
8. Atzeni F., Sarzi-Puttini P., Dell' Acqua D., et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8 (2005) R3
9. Alessandri C., Bombardieri M., Papa N., et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63 (2004) 1218-1221
10. Braun-Moscovici Y., Markovits D., Zinder O., et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 33 (2006) 497-500
11. Plant M.J., Jones P.W., Saklatvala J., et al. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol 25 (1998) 417-426
12. Kroot E.J., de Jong B.A., van Leeuwen M.A., et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43 (2000) 1831-1835
13. Meyer O., Labarre C., Dougados M., et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62 (2003) 120-126
14. Kastbom A., Strandberg G., Lindroos A., et al. ACPA antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63 (2004) 1085-1089
15. Forslind K., Ahlmen M., Eberhardt K., et al. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (ACPA). Ann Rheum Dis 63 (2004) 1090-1095
16. Dubucquoi S., Solau-Gervais E., Lefranc D., et al. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 63 (2004) 415-419
17. Nishimura K., Sugiyama D., Kogata Y.T., et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146 (2007) 797-808
18. Ferraro-Peyret C., Coury F., Tebib J.G., et al. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 6 (2004) R535-R543
19. Moreland L.W., Schiff M.H., Baumgartner S.W., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130 (1999) 478-486
20. Shakoor N., Michalska M., Harris C.A., et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359 (2002) 579-580
21. De Bandt M., Sibilia J., Le Loet X., et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7 (2005) R545-R551
22. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
23. Prevoo M.L., van't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
24. Mikuls T.R., O'Dell J.R., Stoner J.A., et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 50 (2004) 3776-3782
25. De Rycke L., Baeten D., Kruithof E., et al. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 14 (2005) 931-937
26. Caramaschi P., Biasi D., Tonolli E., et al. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 26 (2005) 58-62
27. Atzeni F., Sarzi-Puttini P., Dell' Acqua D., et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8 (2006) R3
28. Vis M., Bos W.H., Wolbink G., et al. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. J Rheumatol 35 (2008) 425-428
29. Charles P.J., Smeenk R.J., De Jong J., et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43 (2000) 2383-2390
30. Comby E., Tanaff P., Mariotte D., et al. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. J Rheumatol 33 (2006) 24-30
31. De Rycke L., Kruithof E., Van Damme N., et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 48 (2003) 1015-1023
32. De Rycke L., Verhelst X., Kruithof E., et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 64 (2005) 299-302
33. Eriksson C., Engstrand S., Sundqvist K.G., et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64 (2005) 403-407
34. Bobbio-Pallavicini F., Alpini C., Caporali R., et al. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 6 (2004) R264-R272
35. Bingham S.J., Buch M.H., Kerr M.A., et al. Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthritis Rheum 50 (2004) 4072-4073
36. Valesini G., Iannuccelli C., Marocchi E., et al. Biological and clinical effects of anti-TNF alpha treatment. Autoimmun Rev 7 (2007) 35-41